candidates Donald Trump election experts Forecasting Headline News immoral Intelwars Joe Biden markets Opinions Politics selection support Voting voting for a politician


This article was contributed by Future Money Trends. 

National polls will tell you which candidate has more support in general, but in the U.S., each and every citizen does not vote on a national level, but on a state-by-state level. In other words, if one resides in California, they will influence which candidate will win in their state alone.

This might create a situation where the popular vote, which is the candidate who gets the most total votes, does not become president.

John Quincy Adams in 1824, Rutherford B. Hayes in 1876, Benjamin Harrison in 1888, George W. Bush in 2000, and Donald Trump in 2016 all won despite losing in the popular vote.

This system, where each resident can only influence locally, is called the electoral college, and it is only practiced in the United States, even though surveys show that between 60% and 80% of Americans don’t approve of it.


  1. This system is based on the number of congressmen that serve in the House of Representatives.

Each state also gets to send two senators to the Senate.

Here’s how this works in real life: in Texas, there are just over 25M residents, so it has 36 congressmen in the House. A state like Vermont is tiny, with less than 650,000 residents, so it has one congressman. The way the electoral college works is Texas gets 36 votes for each congressman and two for its Senators, so it’s worth 38 votes in Tuesday’s elections, compared with Vermont’s 1 congressman + 2 Senators, which gets them 3 votes on Tuesday.

This is just one example. What this does is make it so that each vote is not equal to another due to the number of residents each delegate ends up representing.

Take Oregon, which will vote for Biden. It is worth seven votes. Its population is 4.2M, so it means each delegate is in charge of 600,000 voters (4,200,000 / 7 = 600,000). In other words, every 600,000 people are worth one vote. In red-voting Montana, there are 1.07M residents, which influence three votes, so every 356,000 voters are worth a delegate. This makes their votes more valuable.

  1. Swing states: in areas that are known for changing their minds between Democrats and Republicans, therefore, the two candidates campaign, rally, blow their ad budget, and put in the effort, whereas in states they are comfortably in the lead in or have no prayer of winning, they would not spend a second.

In 2016, in New York, a blue state, 2.8M people voted for Trump, but since Hillary got 4.5M votes, those people’s political opinions got buried.

This system goes back to the early part of the United States when it made more sense, but it seems to be inefficient for the 21st century.


Back to the markets, we can see that as hedge fund manager David Einhorn says, fundamentals have begun mattering since September 2nd because liquidity isn’t enough to move prices higher anymore.

This is a warning sign shouting at us.

Be on the lookout for our special PRESIDENTIAL UPDATE Tuesday AM!


The post It WOULDN’T Take Much: Markets COULD IMPLODE! first appeared on SHTF Plan – When It Hits The Fan, Don't Say We Didn't Warn You.

Big Pharma candidates COVID-19 distribution drugmakers genetic material Headline News Immune System Intelwars late stages mandatory Military Pfizer RNA. mRNA Scientists Trial trials two dose vaccines

Pfizer’s Late Stage COVID-19 Vaccine Trials Near Completion

Pfizer, the drugmaker of one of the COVID-19 vaccines said nearly 36,000 of the volunteers have already received the second of its two-dose of the vaccine. This vaccine is in the very late stages of trials now.

The phase three trials are a critical last step needed to get the vaccines cleared for distribution. Three other U.S.-backed candidates are in phase three: Pfizer expects to apply for an emergency use authorization with the Food and Drug Administration next month.

Trump: “The Military Is Ready To Deliver A Vaccine”

[This vaccine] contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus.

In September, Pfizer expanded the enrollment of its phase three trial to up to 44,000 volunteers from the initial target of up to 30,000. The company said the expansion would allow it to further increase diversity in the trial as well as include adolescents as young as 16 years old and people with preexisting conditions. –CNBC

Pfizer said their data monitoring board, which will assess whether the trial has been successful, has not conducted an interim efficacy analysis yet.

Pfizer Begins Mass Production of COVID-19 Vaccines Anticipating EUA Approval

Pfizer has already begun the mass production of its COVID-19 vaccines even though they are still at the end of phase three trials. It’s too bad people are going to line up to get injected with this concoction. Once it is approved, expect the military and other private companies to begin rolling out this vaccine.

Trump: “The Military Is Ready To Deliver A Vaccine”

FedEx Readies A Plan To Help Distribute COVID-19 Vaccines

Three other United States government-backed vaccine candidates are in phase three also: Moderna, AstraZeneca, and Johnson & Johnson. Be aware that this vaccine will be coming and know what you intend to do.  This may not be “mandatory” but the punishment for not taking it could be harsh.

The post Pfizer’s Late Stage COVID-19 Vaccine Trials Near Completion first appeared on SHTF Plan – When It Hits The Fan, Don't Say We Didn't Warn You.